A Research Study to See How Semaglutide Works Compared to Placebo in People With Type 2 Diabetes and Chronic Kidney Disease
- Conditions
- Diabetes Mellitus, Type 2
- Interventions
- Drug: Placebo (semaglutide)
- Registration Number
- NCT03819153
- Lead Sponsor
- Novo Nordisk A/S
- Brief Summary
The researchers are doing this study to see if semaglutide can slow down the growth and worsening of chronic kidney disease in people with type 2 diabetes. Participants will get semaglutide (active medicine) or placebo ('dummy medicine'). This is known as participants' study medicine - which treatment participants get is decided by chance. Semaglutide is a medicine, doctors can prescribe in some countries for the treatment of type 2 diabetes. Participants will get the study medicine in a pen. Participants will use the pen to inject the medicine in a skin fold once a week. The study will close when there is enough information collected to show clear result of the study. The total time participants will be in this study is about 3 to 5 years, but it could be longer.
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- COMPLETED
- Sex
- All
- Target Recruitment
- 3533
-
Male or female, age above or equal to 18 years at the time of signing informed consent. Japan: Male or female, age above or equal to 20 years at the time of signing informed consent
-
Diagnosed with type 2 diabetes mellitus
-
HbA1c less than or equal to 10% (less than or equal to 86 mmol/mol)
-
Renal impairment defined either by:
- serum creatinine-based eGFR greater than or equal to 50 and less than or equal to 75 mL/min/1.73 m^2 (CKD-EPI) and UACR greater than 300 and less than 5000 mg/g or
- serum creatinine-based eGFR greater than or equal to 25 and less than 50 mL/min/1.73 m^2 (CKD-EPI) and UACR greater than 100 and less than 5000 mg/g
-
Treatment with maximum labelled or tolerated dose of a renin-angiotensin-aldosterone system (RAAS) blocking agent including an angiotensin converting enzyme (ACE) inhibitor or an angiotensin II receptor blocker (ARB), unless such treatment is contraindicated or not tolerated. Treatment dose must be stable for at least 4 weeks prior to the date of the laboratory assessments used for determination of the inclusion criteria for renal impairment and kept stable until screening
- Congenital or hereditary kidney diseases including polycystic kidney disease, autoimmune kidney diseases including glomerulonephritis or congenital urinary tract malformations
- Use of any glucagon-like peptide-1 (GLP-1) receptor agonist within 30 days prior to screening
- Myocardial infarction, stroke, hospitalisation for unstable angina pectoris or transient ischaemic attack within 60 days prior to the day of screening
- Presently classified as being in New York Heart Association (NYHA) Class IV heart failure
- Planned coronary, carotid or peripheral artery revascularisation
- Current (or within 90 days) chronic or intermittent haemodialysis or peritoneal dialysis
- Uncontrolled and potentially unstable diabetic retinopathy or maculopathy. Verified by a fundus examination performed within the past 90 days prior to screening or in the period between screening and randomisation. Pharmacological pupil-dilation is a requirement unless using a digital fundus photography camera specified for non-dilated examination
Study & Design
- Study Type
- INTERVENTIONAL
- Study Design
- PARALLEL
- Arm && Interventions
Group Intervention Description Placebo Placebo (semaglutide) Participants are to receive placebo (semglutide) for up to 5 years or more (event driven). The trial is event driven with a pre-defined minimum number of renal endpoint events for the primary endpoint. Semaglutide Semaglutide Participants are to receive semglutide for up to 5 years or more (event driven). The trial is event driven with a pre-defined minimum number of renal endpoint events for the primary endpoint.
- Primary Outcome Measures
Name Time Method Number of Participants From Time of Randomization to First Occurrence of Onset of Persistent ≥50% Reduction in eGFR(CKD-EPI); Onset of Persistent eGFR(CKD-EPI) <15mL/Min/1.73m^2; Initiation of Chronic Renal Replacement Therapy; Renal Death; CV Death From Week 0 up to Week 234 Number of participants with first composite renal event i.e., from time of randomization to first occurrence of an onset of persistent greater than or equal to (≥) 50 percent (%) reduction in estimated glomerular filtration rate (eGFR) (chronic kidney disease - epidemiology collaboration \[CKD-EPI\]), onset of persistent eGFR (CKD-EPI) \<15 milliliter per minute per 1.73 meter square (mL/min/1.73m\^2), initiation of chronic renal replacement therapy (dialysis or kidney transplantation), renal death, and cardiovascular (CV) death combined data were reported in this outcome measure.
- Secondary Outcome Measures
Name Time Method Change From Baseline in Systolic Blood Pressure at Week 104 Baseline (Week 0), Week 104 Change in systolic blood pressure from Week 0 to Week 104 during in-trial period were presented. In-trial observation period was defined as the period from date of randomization to the first of (both inclusive): date of follow-up visit, date when participant withdrew consent, date of last contact with participant (for participant lost to follow-up), and date of death.
Change From Baseline in Diastolic Blood Pressure at Week 104 Baseline (Week 0), Week 104 Change in diastolic blood pressure from Week 0 to Week 104 during in-trial period were reported. In-trial observation period was defined as the period from date of randomization to the first of (both inclusive): date of follow-up visit, date when participant withdrew consent, date of last contact with participant (for participant lost to follow-up), and date of death.
Number of Participants From Time of Randomization to Occurrence of Onset of Persistent ≥50% Reduction in eGFR (CKD-EPI) From Week 0 up to Week 234 Number of participants from time of randomization to time to occurrence of onset of persistent ≥50% reduction in eGFR (CKD-EPI) were reported. In-trial observation period was defined as the period from date of randomization to the first of (both inclusive): date of follow-up visit, date when participant withdrew consent, date of last contact with participant (for participant lost to follow-up), and date of death.
Annual Rate of Change in eGFR (CKD-EPI) (Total eGFR Slope) From Week 0 up to Week 234 Annual rate of change in Total eGFR slope CKD-EPI were reported from baseline at Week 234 in-trial period. eGFR was calculated using the CKD-EPI formula. In-trial observation period was defined as the period from date of randomization to the first of (both inclusive): date of follow-up visit, date when participant withdrew consent, date of last contact with participant (for participant lost to follow-up), and date of death.
Number of Participants From Time of Randomization to Occurrence of Onset of Persistent eGFR (CKD-EPI) <15mL/Min/1.73m^2 From Week 0 up to Week 234 Number of participants from time of randomization to time to occurrence of onset of persistent eGFR (CKD-EPI) \<15 mL/min/1.73m\^2 were reported. In-trial observation period was defined as the period from date of randomization to the first of (both inclusive): date of follow-up visit, date when participant withdrew consent, date of last contact with participant (for participant lost to follow-up), and date of death.
Number of Participants From Time of Randomization to Occurrence of Initiation of Chronic Renal Replacement Therapy From Week 0 up to Week 234 Number of participants from time of randomization to time to occurrence of initiation of chronic renal replacement therapy (dialysis or kidney transplantation) were reported. In-trial observation period was defined as the period from date of randomization to the first of (both inclusive): date of follow-up visit, date when participant withdrew consent, date of last contact with participant (for participant lost to follow-up), and date of death.
Number of Participants From Time of Randomization to Occurrence of Renal Death From Week 0 up to Week 234 Number of participants from time of randomization to time to occurrence of renal death were reported. In-trial observation period was defined as the period from date of randomization to the first of (both inclusive): date of follow-up visit, date when participant withdrew consent, date of last contact with participant (for participant lost to follow-up), and date of death.
Number of Participants From Time of Randomization to Occurrence of CV Death From Week 0 up to Week 234 Number of participants from time of randomization to time to occurrence of CV death were reported. In-trial observation period was defined as the period from date of randomization to the first of (both inclusive): date of follow-up visit, date when participant withdrew consent, date of last contact with participant (for participant lost to follow-up), and date of death.
Annual Rate of Change in eGFR (Chronic Kidney Disease CKD-EPI) (Chronic eGFR Slope) Week 12, Week 234 Annual rate of change in eGFR in terms of chronic kidney disease CKD-EPI were reported from Week 12 to Week 234 in-trial period. eGFR was calculated using the CKD-EPI formula. In-trial observation period was defined as the period from date of randomization to the first of (both inclusive): date of follow-up visit, date when participant withdrew consent, date of last contact with participant (for participant lost to follow-up), and date of death.
Change From Baseline in eGFR (CKD-EPI) at Week 12 Baseline (Week 0), Week 12 Change from baseline in eGFR at Week 12 during in-trial period were reported. In-trial observation period was defined as the period from date of randomization to the first of (both inclusive): date of follow-up visit, date when participant withdrew consent, date of last contact with participant (for participant lost to follow-up), and date of death.
Change From Baseline in eGFR (Cystatin C CKD-EPI) at Week 104 Baseline (Week 0), Week 104 Changes from baseline in eGFR (cystatin C) at Week 104 in-trial period were reported. Cystatin C was calculated using the CKD-EPI formula. In-trial observation period was defined as the period from date of randomization to the first of (both inclusive): date of follow-up visit, date when participant withdrew consent, date of last contact with participant (for participant lost to follow-up), and date of death.
Change From Baseline in Urinary Albumin-to-creatinine Ratio (UACR) at Week 104: Ratio to Baseline Baseline (Week 0), Week 104 Change from baseline in UACR (ratio to baseline) at Week 104 in-trial period were reported. For UACR, the baseline assessment is defined as the mean of the two assessments from the randomization visit. In-trial observation period was defined as the period from date of randomization to the first of (both inclusive): date of follow-up visit, date when participant withdrew consent, date of last contact with participant (for participant lost to follow-up), and date of death.
Number of Participants From Time of Randomization to Time to First Occurrence of a Major Adverse Cardiovascular Event (MACE): Acute Myocardial Infarction (Non Fatal); Non-fatal Stroke; and CV Death From Week 0 up to Week 234 Number of participants who reported first occurence of non-fatal acute myocardial infarction, non-fatal stroke, and CV death combined data were presented from Week 0 up to Week 234 during on-treatment period. MACE consisted of non-fatal acute myocardial infarction, cardiovascular death and non-fatal stroke. First on-treatment period is defined as period from date of first dose until first time where no dose had been administered within 5 weeks (35 days) or end of the in-trial period, whichever came first.
Number of Participants From Time of Randomization to Time to Occurrence of All-cause Death From Week 0 up to Week 234 Number of participants who reported occurence of deaths from Week 0 up to Week 234 during in-trial period were presented. In-trial observation period was defined as the period from date of randomization to the first of (both inclusive): date of follow-up visit, date when participant withdrew consent, date of last contact with participant (for participant lost to follow-up), and date of death.
Number of Participants From Time of Randomization to Time to Occurrence of Each of the Individual Components of the Confirmatory Secondary MACE Endpoint: Non-fatal Myocardial Infarction From Week 0 up to Week 234 Number of participants who reported occurrence of non-fatal acute myocardial infarction from Week 0 up to Week 234 during in-trial period were presented. In-trial observation period was defined as the period from date of randomization to the first of (both inclusive): date of follow-up visit, date when participant withdrew consent, date of last contact with participant (for participant lost to follow-up), and date of death.
Number of Participants From Time of Randomization to Time to Occurrence of Each of the Individual Components of the Confirmatory Secondary MACE Endpoint: Non-fatal Stroke From Week 0 up to Week 234 Number of participants who reported occurrence of non-fatal stroke from Week 0 up to Week 234 during in-trial period were presented. In-trial observation period was defined as the period from date of randomization to the first of (both inclusive): date of follow-up visit, date when participant withdrew consent, date of last contact with participant (for participant lost to follow-up), and date of death.
Number of Participants From Time of Randomization to Time to First Occurrence of Major Adverse Limb Events (MALE): Acute Limb Ischaemia Hospitalization and Chronic Limb Ischaemia Hospitalization From Week 0 up to Week 234 Number of participants with combined data of first occurence of acute limb ischaemia hospitalization and chronic limb ischaemia hospitalization from Week 0 up to Week 234 during on-treatment period were presented. MALE consisted of acute and chronic limb ischaemia hospitalisation.
Number of Participants With Acute Limb Ischaemia Hospitalization and Chronic Limb Ischaemia Hospitalization From Week 0 up to Week 234 Number of participants of acute limb ischaemia hospitalization and chronic limb ischaemia hospitalization from Week 0 up to Week 234 during in-trial period were presented. MALE consisted of acute and chronic limb ischaemia hospitalisation. In-trial observation period was defined as the period from date of randomization to the first of (both inclusive): date of follow-up visit, date when participant withdrew consent, date of last contact with participant (for participant lost to follow-up), and date of death.
Change From Baseline in Body Weight at Week 104 Baeline (Week 0), Week 104 Change in body weight from Week 0 up to Week 104 during in-trial period, measured in kilograms, were presented. In-trial observation period was defined as the period from date of randomization to the first of (both inclusive): date of follow-up visit, date when participant withdrew consent, date of last contact with participant (for participant lost to follow-up), and date of death.
Change From Baseline in Glycosylated Haemoglobin (HbA1c) at Week 104 Baseline (Week 0), Week 104 Change in HbA1c from Week 0 to Week 104 during in-trial period, measured in percentage point of HbA1c, were presented. In-trial observation period was defined as the period from date of randomization to the first of (both inclusive): date of follow-up visit, date when participant withdrew consent, date of last contact with participant (for participant lost to follow-up), and date of death.
Number of Severe Hypoglycaemic Episodes From Week 0 up to Week 234 The number of severe hypoglycaemic episodes (such as the seriousness of hypoglycaemia, contributing factors, seizures, and unconsciousness; classified by American Diabetes Association) observed during the in-trial period were reported in this endpoint. In-trial observation period was defined as the period from date of randomization to the first of (both inclusive): date of follow-up visit, date when participant withdrew consent, date of last contact with participant (for participant lost to follow-up), and date of death.
Trial Locations
- Locations (407)
Rocky Mount Reg VA Med-DN
🇺🇸Aurora, Colorado, United States
Milestone Research
🇨🇦London, Ontario, Canada
LMC Research Inc. Ottawa
🇨🇦Nepean, Ontario, Canada
Lakeridge Health
🇨🇦Oshawa, Ontario, Canada
Dr. James Cha
🇨🇦Oshawa, Ontario, Canada
King Street Research
🇨🇦Oshawa, Ontario, Canada
Bluewater Clin Res Group, Inc.
🇨🇦Sarnia, Ontario, Canada
Bluewater Clin Res Group,Inc
🇨🇦Sarnia, Ontario, Canada
Winterberry Family Medicine
🇨🇦Stoney Creek, Ontario, Canada
LMC Endo Centres Ltd.(Bayview)
🇨🇦Toronto, Ontario, Canada
UHN-Toronto General Hospital
🇨🇦Toronto, Ontario, Canada
Medizinische Klinik 4, Universitätsklinikum Erlangen
🇩🇪Erlangen, Germany
InnoDiab Forschung GmbH
🇩🇪Essen, Germany
Praxis Dr. med. M. Esser
🇩🇪Essen, Germany
Wendisch/Dahl Hamburg
🇩🇪Hamburg, Germany
Institut für Diabetesforschung GmbH Münster - Dr. med. Rose
🇩🇪Münster, Germany
Zentrum für klinische Studien Alexander Segner
🇩🇪Saint Ingbert-Oberwürzbach, Germany
University Hospital of Athens ATTIKON
🇬🇷Athens, Attica, Greece
Iatriko Psychicou Private Clinic
🇬🇷Athens, Greece
General hospital of Athens 'G.Gennimatas'
🇬🇷Athens, Greece
Iatriko Athinon 'Palaiou Falirou'
🇬🇷Athens, Greece
General Hospital of Athens "Laiko", Nephrology Clinic
🇬🇷Athens, Greece
General Hospital of Lamia
🇬🇷Lamia, Greece
General University Hospital of Patras,Nephrology clinic
🇬🇷Rio, Patra, Greece
AHEPA General University Hospital
🇬🇷Thessaloniki, Greece
"Ippokrateio" G.H. of Thessaloniki
🇬🇷Thessaloniki, Greece
General Hospital of Thessaloniki "Ippokrateio"
🇬🇷Thessaloniki, Greece
EUROMEDICA Gen Clinic The/ki, Endocrin,Metabolism,Diabetes
🇬🇷Thessaloniki, Greece
"Thermi" Private Hosital
🇬🇷Thessaloniki, Greece
Genl Hosp of Thessaloniki, Papageorgiou ,Nephrology clinic
🇬🇷Thessaloniki, Greece
Max Super Speciality Hospital, Saket
🇮🇳New Delhi, Delhi, India
Penza Regional Clinical Hospital named after N.N. Burdenko
🇷🇺Penza, Russian Federation
Diabetes Care Centre & CDE Centre
🇿🇦Benoni, Gauteng, South Africa
LCS Clinical Research Unit
🇿🇦Cosmo City, Gauteng, South Africa
MEDIVASA, s.r.o., Diabetologicka ambulancia
🇸🇰Zilina, Slovakia
Creekside Endocrine Associates, PC
🇺🇸Denver, Colorado, United States
Oceane 7 Medical & Research Center, Inc.
🇺🇸Miami, Florida, United States
International Physicians Research
🇺🇸Miami, Florida, United States
South Broward Research LLC
🇺🇸Miramar, Florida, United States
Saltzer Medical Group Research
🇺🇸Nampa, Idaho, United States
Apex Medical Research Inc
🇺🇸Chicago, Illinois, United States
Clinical Invest Special_Gurnee
🇺🇸Gurnee, Illinois, United States
North Suburban Nephrology LLC
🇺🇸Gurnee, Illinois, United States
Velocity Clin. Res Valparaiso
🇺🇸Valparaiso, Indiana, United States
West Broadway Clinic
🇺🇸Council Bluffs, Iowa, United States
Four Rivers Clinical Research Inc
🇺🇸Paducah, Kentucky, United States
Elite Research Center
🇺🇸Flint, Michigan, United States
Carlos Arauz-Pacheco Md, Pa
🇺🇸Rockwall, Texas, United States
Univ Of Texas Hlth Science Cntr
🇺🇸San Antonio, Texas, United States
Sun Research Institute
🇺🇸San Antonio, Texas, United States
Briggs Clinical Research, LLC
🇺🇸San Antonio, Texas, United States
VIP Trials
🇺🇸San Antonio, Texas, United States
NE Clin Res of San Antonio
🇺🇸San Antonio, Texas, United States
Simcare Medical Research, LLC
🇺🇸Sugar Land, Texas, United States
Hamilton Med Res Group
🇨🇦Hamilton, Ontario, Canada
Ramaiah Memorial Hospital
🇮🇳Bangalore, Karnataka, India
BGS Global Hospitals
🇮🇳Bangalore, Karnataka, India
Lifecare Hospital and Research Centre
🇮🇳Bangalore, Karnataka, India
Sir Ganga Ram Hospital
🇮🇳New Delhi, India
Diabetes Clinic Wolfson MC
🇮🇱Holon, Israel
Diabetes Unit Hadassah Ein Karem MC
🇮🇱Jerusalem, Israel
Meir Medical Center
🇮🇱Kfar Saba, Israel
Kaplan Medical Center_Rehovot
🇮🇱Rehovot, Israel
Istituto Scientifico San Raffaele
🇮🇹Milano, MI, Italy
AOUPol.Giaccone UOC Malattie Endocrine,Ricambio e Nutrizione
🇮🇹Palermo, PA, Italy
Presidio Ospedaliero Cisanello
🇮🇹Pisa, PI, Italy
AO Papa Giovanni XXIII UOC malattie Endocrine 1-Diabetologia
🇮🇹Bergamo, Italy
Azienda Ospedaliera Papa Giovanni XXIII
🇮🇹Bergamo, Italy
Ospedale Maggiore Policlinico UO Endocrinologia Diabetolgia
🇮🇹Milano, Italy
Azienda Ospedaliera Luigi Sacco
🇮🇹Milano, Italy
Azienda Ospealiero Universitaria Policlinico Umberto I
🇮🇹Roma, Italy
Azienda Ospedaliero - Universitaria Sant'Andrea
🇮🇹Roma, Italy
Naka Kinen Clinic
🇯🇵Ibaraki, Japan
Uji Tokushukai Medical Center
🇯🇵Kyoto, Japan
Aurora MedFort LLC
🇷🇺Saint Petersburg, Russian Federation
Regional Endocrinological Dispensary
🇷🇺Stavropol, Russian Federation
Ulianovsk Regional Clinical Hospital
🇷🇺Ulianovsk, Russian Federation
Voronezh Regional Clinical Consultive-diagnostic Centre
🇷🇺Voronezh, Russian Federation
Solovyev Clinical Emergency Hospital
🇷🇺Yaroslavl, Russian Federation
Polyclinic #2 in Yoshkar-Ola
🇷🇺Yoshkar-Ola, Russian Federation
MEDISPEKTRUM s.r.o.
🇸🇰Bratislava, Slovakia
FMC - dialyzacne sluzby, s.r.o.
🇸🇰Kosice, Slovakia
Narodny Endokrinologicky a diabetologicky ustav
🇸🇰Lubochna, Slovakia
IN-DIA s.r.o.
🇸🇰Lucenec, Slovakia
DIABETIK s.r.o.
🇸🇰Nitra, Slovakia
Diabetologicka ambulancia MEDIKARD, s.r.o.
🇸🇰Presov, Slovakia
ARETEUS s.r.o.
🇸🇰Trebisov, Slovakia
MUDr. Jana Rociakova s.r.o., ambulancia vnutorneho lekarstva
🇸🇰Zilina, Slovakia
FMC- dialyzacne sluzby, s.r.o.
🇸🇰Zilina, Slovakia
Soweto Clinical Trial Centre
🇿🇦Johannesburg, Gauteng, South Africa
Hemant Makan
🇿🇦Johannesburg, Gauteng, South Africa
UZ Leuven - Endocrinology
🇧🇪Leuven, Belgium
Osteo Medic s.c. Artur Racewicz Jerzy Supronik
🇵🇱Bialystok, Poland
NZOZ WITAMED Poradnia Diabetologiczna
🇵🇱Kielce, Poland
Wojewodzki Szpital Specjalistyczny w Olsztynie
🇵🇱Olsztyn, Poland
Centre hospitalier universitaire de Liège (CHU de Liège)
🇧🇪Liège, Belgium
Centrum Medyczne "Diabetika"
🇵🇱Radom, Poland
Instituto de Ensino e Pesquisa Clínica do Ceará Ltda
🇧🇷Fortaleza, Ceara, Brazil
Instituto Pró-Renal Brasil
🇧🇷Curitiba, Parana, Brazil
Núcleo de Pesquisa Clínica do Rio Grande do Sul Ltda.
🇧🇷Porto Alegre, Rio Grande Do Sul, Brazil
Hospital e Maternidade Dr. Christovão da Gama S.A.
🇧🇷Santo André, Sao Paulo, Brazil
Instituto de Pesquisa Clinica (IPEC)
🇧🇷São Paulo, Sao Paulo, Brazil
CPQuali Pesquisa Clínica Ltda
🇧🇷São Paulo, Sao Paulo, Brazil
CPCLIN - Centro de Pesquisas Clínicas
🇧🇷São Paulo, Sao Paulo, Brazil
Centro Médico Hospital da Bahia
🇧🇷Bahia, Brazil
Medical centre "Zdrave 1" OOD
🇧🇬Kozloduy, Bulgaria
UMHAT "Kaspela", Depart. Endocrinology and Metab. Diseases
🇧🇬Plovdiv, Bulgaria
MHAT "Dr. Ivan Seliminski"-Sliven
🇧🇬Sliven, Bulgaria
"Nader Yabrudi - ASMPVBE Individual practice"
🇧🇬Smolyan, Bulgaria
UMHAT Aleksandrovska
🇧🇬Sofia, Bulgaria
Medical Center Synexus Sofia
🇧🇬Sofia, Bulgaria
Medical Center "Nov Rehabilitatsionen center" EOOD
🇧🇬Stara Zagora, Bulgaria
LMC Clin Res Inc. Calgary
🇨🇦Calgary, Alberta, Canada
University of Calgary
🇨🇦Calgary, Alberta, Canada
The Bailey Clinic
🇨🇦Red Deer, Alberta, Canada
BC Diabetes Canada
🇨🇦Vancouver, British Columbia, Canada
UZA - UZ Antwerpen - Department of Endocrinology
🇧🇪Edegem, Belgium
Amsterdam UMC Lokatie VUMC
🇳🇱Amsterdam, Netherlands
Rijnstate Ziekenhuis
🇳🇱Arnhem, Netherlands
UZ Gent - Endocrinologie - Diabetologie
🇧🇪Gent, Belgium
Tergooi, locatie Hilversum
🇳🇱Hilversum, Netherlands
Clinical Research of Cent FL
🇺🇸Winter Haven, Florida, United States
Endeavor Health
🇺🇸Skokie, Illinois, United States
Academy of Diabetes, T&E
🇺🇸El Paso, Texas, United States
AZ Delta - Roeselare
🇧🇪Roeselare, Belgium
Premier Clinical Trial Research Network (PCTRN)
🇨🇦Hamilton, Ontario, Canada
Peking University People's Hospital-Endocrinology
🇨🇳Beijing, Beijing, China
Beijing Pinggu Hospital-Endocrinology
🇨🇳Beijing, Beijing, China
The Affiliated Hospital of Jiangsu University-Endocrinology
🇨🇳Zhenjiang, Jiangsu, China
Herz- und Diabeteszentrum NRW - Bad Oeynhausen
🇩🇪Bad Oeynhausen, Germany
Prof Rayner_Division of Nephrology
🇿🇦Cape Town, Western Cape, South Africa
Dr. Terence Hart
🇺🇸Tuscumbia, Alabama, United States
California Inst Of Renal Res
🇺🇸Chula Vista, California, United States
John Muir Physician Network
🇺🇸Concord, California, United States
John Muir Physicians Network
🇺🇸Concord, California, United States
Valley Research
🇺🇸Fresno, California, United States
California Institute of Renal Research
🇺🇸La Mesa, California, United States
First Valley Med Grp Lancaster
🇺🇸Lancaster, California, United States
Clinical Trials Research_Sacramento
🇺🇸Lincoln, California, United States
VA Loma Linda Hlthcr Sys
🇺🇸Loma Linda, California, United States
Long Beach Center For Clinical Research
🇺🇸Long Beach, California, United States
VA Long Beach Healthcare System
🇺🇸Long Beach, California, United States
Academic Medical Research Institute
🇺🇸Los Angeles, California, United States
Universitair Medisch Centrum Utrecht
🇳🇱Utrecht, Netherlands
Valley Renal Medical Group Research
🇺🇸Northridge, California, United States
Desert Oasis Hlthcr Med Group
🇺🇸Palm Springs, California, United States
Saviers Medical Group
🇺🇸Port Hueneme, California, United States
Inland Empire Clin Trials LLC
🇺🇸Rialto, California, United States
Sierra Clinical Research
🇺🇸Roseville, California, United States
California Research Foundation
🇺🇸San Diego, California, United States
N America Res Inst - San Dimas
🇺🇸San Dimas, California, United States
NorCal Endocrinology and Internal Medicine
🇺🇸San Ramon, California, United States
Lundquist Inst-Biomed Innovtn
🇺🇸Torrance, California, United States
San Fernando Valley Hlth Inst
🇺🇸West Hills, California, United States
BayCare Medical Group - Endocrinology
🇺🇸Clearwater, Florida, United States
Horizon Rs Grp, Coral Gbls
🇺🇸Coral Gables, Florida, United States
Cesar Figueroa M.D. P.A.
🇺🇸Delray Beach, Florida, United States
Northeast Research Institute
🇺🇸Saint Augustine, Florida, United States
Palmetto Medical General Plaza
🇺🇸Hialeah, Florida, United States
Encore Medical Research LLC
🇺🇸Hollywood, Florida, United States
Homestead Associates In Research
🇺🇸Homestead, Florida, United States
San Marcus Res Clin Miami Lakes
🇺🇸Miami Lakes, Florida, United States
Floridian Clinical Research, LLC
🇺🇸Miami Lakes, Florida, United States
Life Spring Research
🇺🇸Miami, Florida, United States
Suncoast Clinical Research, Inc.
🇺🇸New Port Richey, Florida, United States
Hanson Clinical Research Center
🇺🇸Port Charlotte, Florida, United States
Cardiovascular Ctr of Sarasota
🇺🇸Sarasota, Florida, United States
Ellipsis Group
🇺🇸Alpharetta, Georgia, United States
Southeastern Clinical Research Institute, LLC
🇺🇸Augusta, Georgia, United States
Endocrine Research Solutions
🇺🇸Roswell, Georgia, United States
Solaris Clinical Research
🇺🇸Meridian, Idaho, United States
Metropolitan Cardiovascular Consultants, LLC
🇺🇸Beltsville, Maryland, United States
Brigham & Women's Hospital
🇺🇸Boston, Massachusetts, United States
Northern Pines Hlth Ctr, PC
🇺🇸Buckley, Michigan, United States
Aa Mrc Llc
🇺🇸Flint, Michigan, United States
Mayo Clinic
🇺🇸Rochester, Minnesota, United States
Clinical Research Consultants, LLC
🇺🇸Kansas City, Missouri, United States
Washington University_St. Louis_0
🇺🇸Saint Louis, Missouri, United States
Univ of Nebraska Medical CTR
🇺🇸Omaha, Nebraska, United States
Renal Medicine Associates
🇺🇸Albuquerque, New Mexico, United States
Albany Medical College - Endo
🇺🇸Albany, New York, United States
NYU Langone Neph Associates
🇺🇸Mineola, New York, United States
NYU Nephrology Associates
🇺🇸New York, New York, United States
Southgate Medical Group, LLP
🇺🇸West Seneca, New York, United States
UNC Diabetes Care Center_Chapel Hill
🇺🇸Chapel Hill, North Carolina, United States
Carteret Medical Group
🇺🇸Morehead City, North Carolina, United States
Burke Primary Care
🇺🇸Morganton, North Carolina, United States
Eastern Nephr Assoc, PLLC
🇺🇸New Bern, North Carolina, United States
Whiteville Medical Associates
🇺🇸Whiteville, North Carolina, United States
Accellacare
🇺🇸Wilmington, North Carolina, United States
Brookview Hills Research Associates, LLC
🇺🇸Winston-Salem, North Carolina, United States
Cincinnati Veterans Affairs Medical Center
🇺🇸Cincinnati, Ohio, United States
Advanced Med Res Maumee
🇺🇸Maumee, Ohio, United States
Alliance for Multispec Res
🇺🇸Norman, Oklahoma, United States
Heritage Valley Medical Group Inc
🇺🇸Beaver, Pennsylvania, United States
Lycoming Internal Medicine, Inc.
🇺🇸Jersey Shore, Pennsylvania, United States
Northeast Endocrine Metabolic Associates
🇺🇸Philadelphia, Pennsylvania, United States
Main Street Physician's Care
🇺🇸Little River, South Carolina, United States
The Diabetes Center, LLC
🇺🇸Murrells Inlet, South Carolina, United States
Family Medicine of SayeBrook LLC
🇺🇸Myrtle Beach, South Carolina, United States
SC Nephrology and Hypertension
🇺🇸Orangeburg, South Carolina, United States
AM Diabetes And Endocrinology Center
🇺🇸Bartlett, Tennessee, United States
Univ Diab & Endo Consultants
🇺🇸Chattanooga, Tennessee, United States
Vanderbilt Medical Center_Nashville
🇺🇸Nashville, Tennessee, United States
Central Texas Clinical Research
🇺🇸Austin, Texas, United States
Texas Diabetes & Endocrinology, P.A._Austin
🇺🇸Austin, Texas, United States
Research Management, Inc
🇺🇸Austin, Texas, United States
Osvaldo A. Brusco MD PA
🇺🇸Corpus Christi, Texas, United States
Baylor Jack and Jane Hamilton
🇺🇸Dallas, Texas, United States
Research Institute Of Dallas
🇺🇸Dallas, Texas, United States
UT Southwestern Med Cntr
🇺🇸Dallas, Texas, United States
MedResearch Inc
🇺🇸El Paso, Texas, United States
Juno Research, LLC_Houston
🇺🇸Houston, Texas, United States
Southwest Clinical Trials
🇺🇸Houston, Texas, United States
Southwest Houston Research Ltd
🇺🇸Houston, Texas, United States
University of Utah School of Medicine
🇺🇸Salt Lake City, Utah, United States
University of Vermont Medical Center
🇺🇸South Burlington, Vermont, United States
York Clinical Research LLC
🇺🇸Norfolk, Virginia, United States
McGuire VA Medical Center
🇺🇸Richmond, Virginia, United States
VA Medical Center_Salem
🇺🇸Salem, Virginia, United States
Amherst Family Practice P.C.
🇺🇸Winchester, Virginia, United States
Capital Clin Res Ctr,LLC
🇺🇸Olympia, Washington, United States
MultiCare Inst for Res & Innov
🇺🇸Spokane, Washington, United States
Universal Research Group
🇺🇸Tacoma, Washington, United States
Centro de Estudios Renales e Hipertensión Arterial
🇦🇷Villa Dominico, Buenos Aires, Argentina
Centro Diabetológico y Nuticional Dr Alejandro Chertkoff
🇦🇷Buenos Aires, Argentina
Centro Medico Dra. Laura Maffei e Investigacion Clínica Apli
🇦🇷Buenos Aires, Argentina
FEPREVA
🇦🇷Caba, Argentina
Centro de Investigación Clínica
🇦🇷Caba, Argentina
Glenny Corp. S.A
🇦🇷Caba, Argentina
Medical Center of Diabetes and Nutrition
🇦🇷Caba, Argentina
Gosford Renal Research
🇦🇺Gosford, New South Wales, Australia
Royal North Shore Hospital
🇦🇺St Leonards, New South Wales, Australia
Westmead Hospital_Northmead
🇦🇺Westmead, New South Wales, Australia
Core Research Centre
🇦🇺Milton, Queensland, Australia
Monash Health Nephrology
🇦🇺Clayton, Victoria, Australia
St Vincent's Hospital_Fitzroy_0
🇦🇺Fitzroy, Victoria, Australia
Monash University Clinical Trial Centre
🇦🇺Melbourne, Victoria, Australia
The Royal Melbourne Hospital
🇦🇺Parkville, Victoria, Australia
Imeldaziekenhuis - Bonheiden - Department of Endocrinology
🇧🇪Bonheiden, Belgium
Universitair Ziekenhuis Brussel - Diabeteskliniek
🇧🇪Brussel, Belgium
UZ Brussel - Universitair Ziekenhuis Brussel
🇧🇪Brussel, Belgium
Cliniques Universitaires Saint-Luc - Serv Endocrinologie - Diabétologie
🇧🇪Bruxelles, Belgium
Commonwealth Medical Clinic
🇨🇦Mount Pearl, Newfoundland and Labrador, Canada
Eastern Health Authority
🇨🇦St. Johns, Newfoundland and Labrador, Canada
QE II Health - Pharmacy
🇨🇦Halifax, Nova Scotia, Canada
Dr. Harpreet Bajaj
🇨🇦Brampton, Ontario, Canada
Aggarwal and Assoc Ltd.
🇨🇦Brampton, Ontario, Canada
JBN Medical Diagnostic Services Inc.
🇨🇦Burlington, Ontario, Canada
LMC Clin Res Inc. Thornhill
🇨🇦Concord, Ontario, Canada
LMC Endo Ctr (Etobicoke) Ltd
🇨🇦Etobicoke, Ontario, Canada
Mount Sinai Hospital
🇨🇦Toronto, Ontario, Canada
Dr Anil K Gupta Med Prof Corp
🇨🇦Toronto, Ontario, Canada
Dr. Anil K Gupta Med Prof Corp
🇨🇦Toronto, Ontario, Canada
Ctr de rech Clin de Laval
🇨🇦Laval, Quebec, Canada
Clinique de Recherche Medpharmgene Inc.
🇨🇦Montreal, Quebec, Canada
Applied Med Inf Res
🇨🇦Montreal, Quebec, Canada
Centre Medical Acadie
🇨🇦Montreal, Quebec, Canada
Centre de Recherche Saint-Louis
🇨🇦Quebec, Canada
Peking University People's Hospital
🇨🇳Beijing, Beijing, China
Jinan Central Hospital
🇨🇳Ji'nan, Shandong, China
Centre Hospitalier Ardeche Nord
🇫🇷Annonay cedex, France
Hospices Civils de Lyon-Hopital Cardiologique Louis Pradel-2
🇫🇷BRON cedex, France
Centre Hospitalier Universitaire de Caen Normandie- Cote de Nacre-1
🇫🇷Caen, France
Centre Hospitalier Universitaire Grenoble Alpes-Site Nord Michallon-2
🇫🇷Grenoble - Cédex 09, France
Centre Hospitalier Departemental Vendee- La Roche Sur Yon
🇫🇷La Roche-sur-yon, France
Les Hopitaux de Chartres-Hopital Louis Pasteur
🇫🇷Le Coudray, France
Groupe Sos Sante-Hopital Le Creusot-Hotel Dieu-1
🇫🇷Le Creusot, France
Groupe SOS Santé Hôtel Dieu
🇫🇷Le Creusot, France
Fondation Rothschild
🇫🇷Paris, France
Centre Hospitalier Universitaire Reims-Hopital Maison Blanche
🇫🇷Reims, France
Centre Hospitalier Universitaire de Nantes-Hopital Nord Laennec-1
🇫🇷Saint Herblain, France
Hôpital Nord Laënnec- Service D'Endocrinologie
🇫🇷Saint Herblain, France
Centre Hospitalier Universitaire de Toulouse-Hopital Rangueil-2
🇫🇷Toulouse, France
Centre de Recherche Clinique Portes Du Sud
🇫🇷Venissieux, France
Diabetespraxis Mergentheim
🇩🇪Bad Mergentheim, Germany
DaVita Clinical Research Deutschland GmbH
🇩🇪Düsseldorf, Germany
PTE-AOK II. Belgyogyaszati Klinika es Nephrologiai Centrum
🇭🇺Pécs, Baranya Vármegye, Hungary
Lausmed Kft.
🇭🇺Baja, Bács-Kiskun Vármegye, Hungary
Belinus Bt.
🇭🇺Debrecen, Hungary
Siófoki Kórház, Diabetológiai Szakrendelés
🇭🇺Siófok, Hungary
Borbánya Praxis E.Ü. Kft.
🇭🇺Nyíregyháza, Szabolcs-Szatmar Varmegye, Hungary
Péterfy Sándor utcai Kórház
🇭🇺Budapest, Hungary
MED-TIMA Kft.
🇭🇺Budapest, Hungary
Debreceni Egyetem Klinikai Központ Belgyógyászati Klinika D épület
🇭🇺Debrecen, Hungary
Debreceni Egyetem Klinikai Központ Belgyógyászati Klinika
🇭🇺Debrecen, Hungary
Békés Megyei Központi Kórház
🇭🇺Gyula, Hungary
Markusovszky Egyetemi Oktatókórház
🇭🇺Szombathely, Hungary
Endolife Specialty Hospitals
🇮🇳Guntur, Andhra Pradesh, India
Amrita Institute Of Medical Sciences & Research Centre
🇮🇳Kochi, Kerala, India
Calicut Medical College
🇮🇳Kozhikode, Kerala, India
Seth GS medical college and KEM Hospital
🇮🇳Mumbai, Maharashtra, India
Poona hospital and research centre
🇮🇳Pune, Maharashtra, India
The Madras Medical Mission
🇮🇳Chennai, Tamil Nadu, India
Osmania General Hospital
🇮🇳Hyderabad, Telangana, India
MV Hospital and Research Centre
🇮🇳Lucknow, Uttar Pradesh, India
Ajanta ResearchCentre
🇮🇳Lucknow, Uttar Pradesh, India
Sanjay Gandhi Postgraduate Institute of Medical Sciences
🇮🇳Lucknow, Uttar Pradesh, India
Sanjay Gandhi Postgraduate Institute of Medical Science
🇮🇳Lucknow, Uttar Pradesh, India
Apollo Multispeciality Hospital, Kolkata
🇮🇳Kolkata, West Bengal, India
Seino Internal Medicine Clinic
🇯🇵Koriyama-shi, Fukushima, Japan, Japan
Manda Memorial Hospital
🇯🇵Sapporo-shi, Hokkaido, Hokkaido, Japan, Japan
Jinnouchi Hospital
🇯🇵Kumamoto-shi, Kumamoto, Japan, Japan
Heiwadai Hospital
🇯🇵Miyazaki-shi, Miyazaki, Japan
New Tokyo Heart Clinic
🇯🇵Chiba, Japan
Fukui Prefectural Hospital_Fukui
🇯🇵Fukui, Japan
Fukuoka Tokushukai Hospital
🇯🇵Fukuoka, Japan
Kawada Clinic
🇯🇵Gunma, Japan
Sasaki Hospital Internal Medicine
🇯🇵Hokkaido, Japan
Sasaki Internal Medicine
🇯🇵Hokkaido, Japan
Nishiyamado Keiwa Hospital
🇯🇵Ibaraki,, Japan
Kanazawa Medical University Hospital
🇯🇵Ishikawa, Japan
Yokohama Minoru Clinic
🇯🇵Kanagawa, Japan
H.E.C Science Clinic
🇯🇵Kanagawa, Japan
Shonan Takai Clinic
🇯🇵Kanagawa, Japan
Kawasaki Medical School Hospital
🇯🇵Okayama, Japan
Takatsuki Red Cross Hospital
🇯🇵Osaka, Japan
Shimizu Clinic Fusa
🇯🇵Saitama, Japan
Oyama East Clinic
🇯🇵Tochigi, Japan
Tokyo Center Clinic
🇯🇵Tokyo, Japan
Fukuwa Clinic
🇯🇵Tokyo, Japan
Juntendo University Hospital_Tokyo
🇯🇵Tokyo, Japan
The University of Tokyo Hospital
🇯🇵Tokyo, Japan
Kato Clinic of Internal Medicine
🇯🇵Tokyo, Japan
Sugawara Clinic
🇯🇵Tokyo, Japan
University Malaya Medical Centre
🇲🇾Kuala Lumpur, Wilayah Persekutuan Kuala Lumpur, Malaysia
Hospital Sultanah Bahiyah
🇲🇾Alor Setar, Malaysia
Hospital Raja Permaisuri Bainun Ipoh
🇲🇾Ipoh, Perak, Malaysia
Sarawak General Hospital
🇲🇾Kuching, Malaysia
Hospital Pulau Pinang
🇲🇾Pulau Pinang, Malaysia
Hospital Serdang
🇲🇾Serdang, Malaysia
Centro de Atención al Diabetico
🇲🇽Actopan, Hidalgo, Mexico
Inst. Jaliscience de Investigacion en Diabetes y Obesidad SC
🇲🇽Guadalajara, Jalisco, Mexico
Instituto Nacional de Nutricion - Unidad de Inv de Enf Metab
🇲🇽Distrito Federal, México, D.F., Mexico
Instituto Nacional de Ciencias Médicas y Nutrición_Mexico City
🇲🇽Mexico City, México, D.F., Mexico
Centro para el Desarrollo de la Medicina y la Asistencia
🇲🇽Culiacán, Sinaloa, Mexico
Centro de Estudios de Investigación Metabólicos y Cardio
🇲🇽Ciudad Madero, Tamaulipas, Mexico
Noordwest Ziekenhuisgroep
🇳🇱Alkmaar, Netherlands
Ziekenhuis Groep Twente Almelo
🇳🇱Almelo, Netherlands
EB Flevo Research BV
🇳🇱Almere, Netherlands
Meander Medisch Centrum
🇳🇱Amersfoort, Netherlands
OLVG West
🇳🇱Amsterdam, Netherlands
Uniwersytecki Szpital Kliniczny Nr 2 PUM W Szczecinie
🇵🇱Szczecin, Poland
Synexus Polska Sp. z o.o. Oddzial w Warszawie
🇵🇱Warszawa, Poland
Miedzyleski Szpital Specjalistyczny, Oddzial Nefrologiczny
🇵🇱Warszawa, Poland
Prywatny Gabinet Janusz Gumprecht
🇵🇱Zabrze, Poland
Reg. State Budget Healthc. Inst. Regional Clinical Hospital
🇷🇺Barnaul, Russian Federation
City Hospital #5
🇷🇺Barnaul, Russian Federation
Road Clinical Hospital at station Chelyabinsk
🇷🇺Chelyabinsk, Russian Federation
PIH "Clin Hosp "RZD-Medicina" former Kazan OJSC Rus Railways
🇷🇺Kazan, Russian Federation
SAHI Kuzbass Hospital(former Regional clinical hospital)
🇷🇺Kemerovo, Russian Federation
National Medical Research Center of Endocrinology
🇷🇺Moscow, Russian Federation
LLC RC Medical
🇷🇺Novosibirsk, Russian Federation
Limited Law Company "Healthy Family" Medicine Center"
🇷🇺Novosibirsk, Russian Federation
Joint Stock Company "Modern Medical Technologies"
🇷🇺Saint-Petersburg, Russian Federation
Limited Liability Company "Energiya Zdoroviya"
🇷🇺Saint-Petersburg, Russian Federation
Medinet LLC
🇷🇺Saint-Petersburg, Russian Federation
LLC "Endocrinolog"
🇷🇺Samara, Russian Federation
SHI Saratov City Clinical Hospital #9
🇷🇺Saratov, Russian Federation
Regional clinical cardiology dispensary
🇷🇺Saratov, Russian Federation
Wits Bara Clinical Trial Site
🇿🇦Johannesburg, Gauteng, South Africa
Dr A Amod
🇿🇦Durban, KwaZulu-Natal, South Africa
Precise Clinical Solutions (Pty) Ltd
🇿🇦Durban, KwaZulu-Natal, South Africa
Tiervlei Trial Centre
🇿🇦Cape Town, Western Cape, South Africa
Hospital del Mar
🇪🇸Barcelona, Spain
Hospital Vall d'Hebron
🇪🇸Barcelona, Spain
Hospital Público da Mariña
🇪🇸Burela, Spain
Hospital Universitario de Getafe
🇪🇸Getafe, Spain
Hospital Ribera Polusa
🇪🇸Lugo, Spain
Hospital Clínico Universitario de Valencia
🇪🇸Valencia, Spain
Hospital Universitario Doctor Peset
🇪🇸Valencia, Spain
Siriraj Hospital_Bangkoknoi, Bangkok
🇹🇭Bangkoknoi, Bangkok, Bangkok, Thailand
Maharaj Nakorn Chiang Mai Hospital
🇹🇭Chiang Mai, Mueang Chiang Mai District, Thailand
Phramongkutklao Hospital-nephrology
🇹🇭Bangkok, Thailand
Kocaeli University Nephrology Department
🇹🇷Kocaeli, Turkey
SI "Institute of Medical and Social Problems of Disability"
🇺🇦Dnipro, Ukraine
Ivano-Frankivsk Regional Clinical Hospital
🇺🇦Ivano-Frankivsk, Ukraine
CNPI "Kharkiv City Clinical Hospital #27"
🇺🇦Kharkiv, Ukraine
SI "National Institute of Therapy n.a. L.T. Malaya of NAMSU"
🇺🇦Kharkiv, Ukraine
Institute of Endocrinology and Metabolism of AMSU
🇺🇦Kyiv, Ukraine
CI "1st City Clinical Hospital of Poltava City Council"
🇺🇦Poltava, Ukraine
CI "Zaporizhia city clinical hospital #10"
🇺🇦Zaporizhia, Ukraine
King Chulalongkorn Memorial Hospital-Division of Nephrology
🇹🇭Bangkok, Thailand
King Chulalongkorn Memorial Hospital_Bangkok
🇹🇭Bangkok, Thailand
Siriraj Hospital-Nephro
🇹🇭Bangkok, Thailand
Ankara Universitesi Ibni Sina Hastanesi
🇹🇷Ankara, Turkey
Hacettepe Universitesi Tip Fakultesi Nefroloji Bilim Dali
🇹🇷Ankara, Turkey
Gazi University Medical Faculty- Nephrology
🇹🇷Ankara, Turkey
Akdeniz Universitesi Hastanesi Nefroloji Bilim Dali
🇹🇷Antalya, Turkey
Aydin Adnan Menderes University Nephrology
🇹🇷Aydin, Turkey
Istanbul University Cerrahpasa Medical Faculty
🇹🇷Istanbul, Turkey
Istanbul Universitesi Istanbul Tip Fakultesi- Nefroloji
🇹🇷Istanbul, Turkey
Goztepe Egitim Arastirma Hastanesi Nefroloji
🇹🇷Istanbul, Turkey
T.C. Saglik Bakanligi Pendik Egitim ve Arastirma Hastanesi
🇹🇷Istanbul, Turkey
Ege University Medical Faculty
🇹🇷Izmir, Turkey
Kahramanmaras Sutcu Imam University
🇹🇷Kahramanmaras, Turkey
Aberdeen Royal Infirmary
🇬🇧Aberdeen, United Kingdom
Diabetes Centre, Heartlands Hospital, Birmingham
🇬🇧Birmingham, United Kingdom
Ely Bridge Surgery
🇬🇧Cardiff, United Kingdom
Ninewells Hospital
🇬🇧Dundee, United Kingdom
Western General Hospital
🇬🇧Edinburgh, United Kingdom
Glasgow Clinical Research Facility
🇬🇧Glasgow, United Kingdom
The Diabetes Centre
🇬🇧Ipswich, United Kingdom
North Middlesex Hospital
🇬🇧London, United Kingdom
Royal Free - Diabetes
🇬🇧London, United Kingdom
Lister Hospital
🇬🇧Stevenage, United Kingdom
St Georges Hospital
🇬🇧Tooting, United Kingdom